Table 2 Changes in Scores of Scales such as MEQ-19, HAMD-17 for Depressed Patients of Different Types at Various Visit Points
Scale | Group | N | Baseline | End of Week 2 | End of Week 4 | End of Week 8 | End of Week 12 | F-value and P-value |
|---|---|---|---|---|---|---|---|---|
HAMD-17 | Agomelatine Group | 90 | 22.7 ± 6.4 | 14.3 ± 8.1 | 8.5 ± 6.4 | 6.2 ± 5.6 | 4.4 ± 3.9 | FT = 349.318, P < 0.001; FI = 0.227, P = 0.923; FT*I = 3.029, P = 0.084 |
SSRIs Group | 90 | 22.3 ± 4.6 | 13.2 ± 6.3 | 7.1 ± 5.2 | 4.8 ± 4.1 | 3.4 ± 3.3 | ||
HAMA | Agomelatine Group | 90 | 21.0 ± 8.4 | 14.4 ± 9.5 | 8.9 ± 7.4 | 5.5 ± 4.8 | 4.2 ± 4.8 | FT = 184.482, P < 0.001; FI = 1.184, P = 0.320; FT*I = 2.606, P = 0.109 |
SSRIs Group | 90 | 20.0 ± 8.2 | 12.2 ± 5.8 | 7.3 ± 5.5 | 5.1 ± 4.1 | 3.4 ± 3.3 | ||
SHAPS | Agomelatine Group | 90 | 45.4 ± 5.8 | 44.9 ± 6.3 | 44.9 ± 5.2 | 44.1 ± 3.9 | 40.8 ± 5.4 | FT = 6.897, P < 0.001; FI = 0.725, P = 0.576; FT*I = 0.417, P = 0.519 |
SSRIs Group | 90 | 45.6 ± 5.7 | 45.6 ± 4.9 | 44.8 ± 5.3 | 44.4 ± 5.8 | 41.5 ± 5.2 | ||
MFI-20 | Agomelatine Group | 90 | 79.0 ± 12.1 | 63.7 ± 16.5 | 52.8 ± 15.4 | 46.7 ± 13.7 | 43.2 ± 13.9 | FT = 123.830, P < 0.001; FI = 0.315, P = 0.868; FT*I = 0.331, P = 0.566 |
SSRIs Group | 90 | 79.2 ± 11.4 | 62.4 ± 18.6 | 50.5 ± 16.4 | 45.8 ± 15.3 | 42.5 ± 15.5 | ||
MEQ | Agomelatine Group | 90 | 51.8 ± 9.6 | 53.0 ± 8.1 | 55.1 ± 8.8 | 55.7 ± 9.7 | 56.2 ± 10.3 | FT = 4.870, P = 0.001; FI = 0.378, P = 0.824; FT*I = 0.002, P = 0.961 |
SSRIs Group | 90 | 52.9 ± 8.8 | 53.1 ± 9.2 | 54.8 ± 9.5 | 55.5 ± 9.6 | 55.6 ± 9.9 | ||
PSQI | Agomelatine Group | 90 | 14.4 ± 3.4 | 10.3 ± 4.6 | 6.8 ± 3.9 | 6.4 ± 3.8 | 5.3 ± 3.3 | FT = 176.150, P < 0.001; FI = 3.169, P = 0.016; FT*I = 1.067, P = 0.303 |
SSRIs Group | 90 | 14.7 ± 3.3 | 10.8 ± 4.1 | 8.4 ± 4.3 | 6.9 ± 3.9 | 5.6 ± 3.5 |